Approximately 10% of M2 AML patients will develop GS, as a consequence, the t(8;21) and the relative transcript RUNX1-RUNX1T1 represent the most common cytogenetic and molecular abnormalities seen in GS [4]. The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.